North American Protein Degradation Congress | Kisaco Research

North American Protein Degradation Congress

Progressing translation of protein degradation probes into safe, effective therapeutics.

Download Agenda
San Diego, USA
4-6 February, 2020

Just announced: Pre-conference deep dive into ‘Drugging the Proteasome’. Targeting the proteasome for the treatment of disease. February 4th 2020. Enquire for details.

“A lot of data on PROTAC research has been disclosed on this event. And also many leaders in PROTAC shared their experience and concerns about PROTAC development. Many start up companies also delivered their progress. We can discuss future PROTAC directions as well as difficulties with experts from both industry and the academic area, and learned a lot. ”

Yuqing Huang - CFO, Kintor

Why Attend

“The entire bandwidth of the protein degradation field was covered with excellent, carefully prepared presentations” -  Peter von Matt, Novartis

With Arvinas’ PROTAC therapy entering phase 1 clinical trials, Kymeras’ IRAK4 degrader racing through pre-clinical, and Bristol-Myers Squibb approaching complete acquisition of Celgene, it has never been a more exciting time to be working in the field of targeted protein degradation.

Following the global response to the inaugural European Congress earlier this year, the North American Protein Degradation Congress will bring together pharma, biotech, and academic researchers to expand upon one of the hottest drug discovery platforms within the pharmaceutical industry. Delegates will have the opportunity to learn from experts and key thought leaders within the protein degradation space, allowing ideas to be exchanged, partnerships to be built, and difficulties to be addressed in expanding the space of protein degraders beyond our current knowledge.

At the congress, you can expect to hear the following:

  • The latest pre-clinical and clinical data in PROTAC therapy and molecular glues
  • Emerging strategies outside of PROTACs and molecular glues to induce TPD
  • Assessing rates of protein synthesis, degradation, and quantifying protein homeostatic in vivo

Insights into protein degrader PK/PD from mechanistic modelling

Pre-conference day

‘Drugging the Proteasome’

Targeting the proteasome for the treatment of disease

February 4th: Pre-conference deep dive into ‘Drugging the Proteasome’

February 5th-6th: North American Protein Degradation Congress

The day before the main conference, we will be hosting an informational summit specifically on viewing the proteasome as a means for drug discovery and development for the treatment of disease.

At the summit, we will cover:

  • Proteasome inhibition
  • Proteasome activation
  • Proteasome structure and function
  • Latest applications of proteasome targeting in the treatment of disease
  • Targeted protein degradation through ubiquitin-independent mechanisms

For more information please contact [email protected]

Highlights from Europe 2019

Previous attending companies

What attendees say

Talk to our speakers about...

Pre-conference deep dive into ‘Drugging the Proteasome’

4th February 2020

1. The latest development of proteasome inhibitors for the treatment of disease, including new therapeutic areas


2. Strategies to exploit proteasome-related mechanisms for therapeutic benefits


3. Targeting the immunoproteasome in the treatment of human disease in
autoimmunity and oncology


4. The development of proteasome activators for the treatment of
neurodegenerative diseases


5. The induction of targeted protein degradation via ubiquitin-independent pathways which can lead to novel small molecule drug discovery


6. The use of the structure, function, and dynamics of proteasome assembly for therapeutic benefit in human disease

Targeted Protein Degradation

5th-6th February 2020

1. Remaining competitive in the fastest growing field in current medicinal chemistry using the latest clinical and pre-clinical development of targeted protein degraders


2. The development of small molecule degraders using molecular principles of neo-substrate recruitment to identify new targets for therapeutic development


3. Technical considerations needed to evaluate the efficacy and safety of protein degraders in vivo, to better address challenges in translational to animal models


4. Targeted protein degradation and how it can be applied in a therapeutic sense in neurology, cardiology, and hepatology, to expand the range of protein degrader targets


5. How to use lysosomal and autophagy-based mechanisms to induce TDP in proteins and organelles outside of PROTACs and molecular glues


6. PROTAC-specific PK, binding affinities, and cooperativity parameters to better understand PKPD mechanistic modelling


7. Advanced therapy development using proteome-wide studies to assess the rate of protein synthesis and degradation

Who Will Be There

Pharma

Heads of Chemical Biology, Medicinal Chemistry, Proteomics, Discovery Biology, Pharmacology, Computational Biology

Biotech

Founder, Chief Scientific Officer, CEO, Chief Technology Officer

Academic & Research Institutes

Professor - Cell Biology, Research Fellow - Chemoproteomics, Director - Biochemistry

Service Providers

Equipment Manufacturers (Analysis, HTS), CRO/ CMO, Reagents, Delivery/ Computational Providers

Speakers

 

Eric Fischer

Assistant Professor of Biological Chemistry and Molecular Pharmacology
Harvard Medical School

Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation.

Eric Fischer

Assistant Professor of Biological Chemistry and Molecular Pharmacology
Harvard Medical School

Eric Fischer

Assistant Professor of Biological Chemistry and Molecular Pharmacology
Harvard Medical School

Eric Fischer, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and a Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute. His research focuses on understanding the complex mechanisms that underlie function and regulation of multi-component ubiquitin ligases and their role in disease. His work further focuses on new therapeutic approaches such as targeted protein degradation. He co-directs the DFCI Center for Protein Degradation and has been recognized for his pioneering work on the structure of cereblon and the mechanism of action of thalidomide.

 

Marjeta Urh

Director of Research
Promega

My role as Director in R&D at Promega is to develop novel technologies and research tools for analysis of nucleic acids and protein function. The breadth of technologies developed in my group span mass spectrometry, novel immunoassays, analysis of protein-protein and protein-small molecule interactions and targeted protein degradation. In addition, my group is involved in developing applications of Promega core technologies such as HaloTag, NanoBRET, NanoBiT and HiBiT technologies.

Marjeta Urh

Director of Research
Promega

Marjeta Urh

Director of Research
Promega

My role as Director in R&D at Promega is to develop novel technologies and research tools for analysis of nucleic acids and protein function. The breadth of technologies developed in my group span mass spectrometry, novel immunoassays, analysis of protein-protein and protein-small molecule interactions and targeted protein degradation. In addition, my group is involved in developing applications of Promega core technologies such as HaloTag, NanoBRET, NanoBiT and HiBiT technologies.

 

Seth Margolis

Associate Professor, Department of Biological Chemistry
Johns Hopkins University School of Medicine

Dr. Margolis received his Bachelor of Science in Biochemistry at the University of Rochester (Rochester, NY).  In 1999, he joined graduate school at Duke University Medical Center (Durham, North Carolina) in the department of Pharmacology and Cancer Biology.  There, Dr. Margolis completed a doctoral thesis with Dr. Sally Kornbluth focusing on molecular mechanisms of DNA-responsive cell cycle checkpoints using the frog Xenopus egg extract system.  Following completion of a Ph.D., in 2006 Dr. Margolis joined the laboratory of Dr.

Seth Margolis

Associate Professor, Department of Biological Chemistry
Johns Hopkins University School of Medicine

Seth Margolis

Associate Professor, Department of Biological Chemistry
Johns Hopkins University School of Medicine

Dr. Margolis received his Bachelor of Science in Biochemistry at the University of Rochester (Rochester, NY).  In 1999, he joined graduate school at Duke University Medical Center (Durham, North Carolina) in the department of Pharmacology and Cancer Biology.  There, Dr. Margolis completed a doctoral thesis with Dr. Sally Kornbluth focusing on molecular mechanisms of DNA-responsive cell cycle checkpoints using the frog Xenopus egg extract system.  Following completion of a Ph.D., in 2006 Dr. Margolis joined the laboratory of Dr. Michael Greenberg in the department of Neurobiology at Harvard University (Boston, Massachusetts).  During a postdoctoral tenure with the guidance and support of Dr. Greenberg, Dr. Margolis focused his efforts on the molecular pathways that regulate excitatory synapse formation and investigating their relevance to the pathophysiology of the cognitive disorder Angelman Syndrome.  In September 2011, Dr. Margolis joined the Department of Biological Chemistry at the Johns Hopkins University School of Medicine as an Assistant Professor. The vast majority of Dr. Margolis work is centered on understanding how molecular mechanisms that restrict synapses during development are reactivated in neurodevelopmental and neurodegenerative disease. To this end, Dr. Margolis and his group use genetically engineered mouse models of disease and a multidisciplinary approach that combines aspect of molecular biology, biochemistry and in vivo synapse imaging in order to develop hypothesis about the underlying cause of synapse degeneration and cognitive decline.  They then use genetic rescue or stereotactic approaches to target distinct pathways followed by a wide range of behavioral tasks to assay cognitive function and tests their hypotheses.  More recently, Dr. Margolis has developed a new direction focused on cellular protein homeostasis mechanisms related to protein degradation and their impact on changes in the function and physiology of the nervous system. Using a wide range of classic biochemical purification approaches, Dr. Margolis and his team have identified novel proteasome mediated pathways in the nervous system and are just beginning to understand their relevance to health and disease.

 

Phil Chamberlain

Senior Director, Structural and Chemical Biology
Celgene

Phil Chamberlain obtained his BA and D.Phil. degrees from the University of Oxford before traveling to the U.S. to perform his post-doctoral work at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego. Phil joined Celgene, San Diego in 2007 and leads the Structural and Chemical Biology department which provides structural, biochemical and cellular data in support of drug discovery projects.

Phil Chamberlain

Senior Director, Structural and Chemical Biology
Celgene

Phil Chamberlain

Senior Director, Structural and Chemical Biology
Celgene

Phil Chamberlain obtained his BA and D.Phil. degrees from the University of Oxford before traveling to the U.S. to perform his post-doctoral work at the Genomics Institute of the Novartis Research Foundation (GNF) in San Diego. Phil joined Celgene, San Diego in 2007 and leads the Structural and Chemical Biology department which provides structural, biochemical and cellular data in support of drug discovery projects. Phil is known for his work in understanding and extending the action of cereblon modulators, and has published work in this area in journals including Nature and Nature Structural and Molecular Biology.

 

Alexei Kisselev

Associate Professor
Auburn University

Alexei Kisselev

Associate Professor
Auburn University

Alexei Kisselev

Associate Professor
Auburn University
 

Alfred Goldberg

Professor
Harvard Medical School

Alfred Goldberg

Professor
Harvard Medical School

Alfred Goldberg

Professor
Harvard Medical School
 

Andrew Benowitz

Senior Director, Protein Degradation DPU Head
GSK

Andrew Benowitz

Senior Director, Protein Degradation DPU Head
GSK

Andrew Benowitz

Senior Director, Protein Degradation DPU Head
GSK
 

Benham Nabet

Research Fellow
Dana-Farber Cancer Institute

Benham Nabet

Research Fellow
Dana-Farber Cancer Institute

Benham Nabet

Research Fellow
Dana-Farber Cancer Institute
 

Christopher Kirk

President and CSO
Kezar Life Sciences Inc

Christopher Kirk

President and CSO
Kezar Life Sciences Inc

Christopher Kirk

President and CSO
Kezar Life Sciences Inc
 

Daniel Scott

Research Specialist
St. Jude Children's Research Hospital

Daniel Scott

Research Specialist
St. Jude Children's Research Hospital

Daniel Scott

Research Specialist
St. Jude Children's Research Hospital
 

David Rubinsztein

Professor
Cambridge Institute for Medical Research

David Rubinsztein

Professor
Cambridge Institute for Medical Research

David Rubinsztein

Professor
Cambridge Institute for Medical Research
 

Derek Bartlett

Senior Principal Scientist
Pfizer

Derek Bartlett

Senior Principal Scientist
Pfizer

Derek Bartlett

Senior Principal Scientist
Pfizer
 

Dhanusha Nalawansha

Postdoctoral Associate
Yale University

Dhanusha Nalawansha

Postdoctoral Associate
Yale University

Dhanusha Nalawansha

Postdoctoral Associate
Yale University
 

Fleur Ferguson

Research Fellow
Dana-Farber Cancer Institute

Fleur Ferguson

Research Fellow
Dana-Farber Cancer Institute

Fleur Ferguson

Research Fellow
Dana-Farber Cancer Institute
 

Frank Mercurio

CSO
BioTheryX

Frank Mercurio

CSO
BioTheryX

Frank Mercurio

CSO
BioTheryX
 

Hyunsun Jo

Chief Executive Officer
Pin Therapeutics

Hyunsun Jo

Chief Executive Officer
Pin Therapeutics

Hyunsun Jo

Chief Executive Officer
Pin Therapeutics
 

James Winkler

Head of Degrader Technologies
Frontier Medicines

James Winkler

Head of Degrader Technologies
Frontier Medicines

James Winkler

Head of Degrader Technologies
Frontier Medicines
 

John Houston

CEO
Arvinas

John Houston

CEO
Arvinas

John Houston

CEO
Arvinas
 

John Price

Assistant Professor
Brigham Young University

John Price

Assistant Professor
Brigham Young University

John Price

Assistant Professor
Brigham Young University
 

Kandaswamy Vijayan

CEO
Plexium

Kandaswamy Vijayan

CEO
Plexium

Kandaswamy Vijayan

CEO
Plexium
 

Lawrence Dick

Principal
Seofon Consulting

Lawrence Dick

Principal
Seofon Consulting

Lawrence Dick

Principal
Seofon Consulting
 

Marcus Groettrup

Chair of Immunology
Konstanz University

Marcus Groettrup

Chair of Immunology
Konstanz University

Marcus Groettrup

Chair of Immunology
Konstanz University
 

Matthew Bogyo

Group Leader and Professor
Stanford University

Matthew Bogyo

Group Leader and Professor
Stanford University

Matthew Bogyo

Group Leader and Professor
Stanford University
 

Michal Sharon

Associate Professor
The Weizmann Institute

Michal Sharon

Associate Professor
The Weizmann Institute

Michal Sharon

Associate Professor
The Weizmann Institute
 

Nello Mainolfi

Founder, President, CSO
Kymera Therapeutics

Nello Mainolfi

Founder, President, CSO
Kymera Therapeutics

Nello Mainolfi

Founder, President, CSO
Kymera Therapeutics
 

Paola Castaldi

Associate Director, Head of Chemical Biology
AstraZeneca

Paola Castaldi

Associate Director, Head of Chemical Biology
AstraZeneca

Paola Castaldi

Associate Director, Head of Chemical Biology
AstraZeneca
 

Robert Blake

Senior Scientist
Genentech

Robert Blake

Senior Scientist
Genentech

Robert Blake

Senior Scientist
Genentech
 

Robert Tomko

Assistant Professor
Florida State University

Robert Tomko

Assistant Professor
Florida State University

Robert Tomko

Assistant Professor
Florida State University
 

Robin Ketteler

Group Leader
University College London

Robin Ketteler

Group Leader
University College London

Robin Ketteler

Group Leader
University College London
 

Takhar Kasumov

Assistant Professor
Northeast Ohio Medical University

Takhar Kasumov

Assistant Professor
Northeast Ohio Medical University

Takhar Kasumov

Assistant Professor
Northeast Ohio Medical University
 

Zhen-qiang Pan

Professor
Icahn School of Medicine at Mount Sinai

Zhen-qiang Pan

Professor
Icahn School of Medicine at Mount Sinai

Zhen-qiang Pan

Professor
Icahn School of Medicine at Mount Sinai

POSTER SESSION

Looking to showcase your recent work to the protein degradation community?

Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.

Poster abstract submission deadline is on December 18 2019. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.

Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!

If you have any questions please contact [email protected] 

SUBMIT A POSTER ABSTRACT

Gold Partner

Previous Partners

Media Partners

The Agenda

Please download our agenda to find out more information about the congress including the main topics of discussion for the pre-conference deep dive day and the two day congress and preview lineup of speakers.

What you can expect from the 2020 congress:

  • 200+ participants from leading industry players within big pharma and biotech along with expert academics in the ubiquitin

    space.

  • An open forum to share the latest in vivo and in vitro data and insights and foster collaboration. 
  • 18+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
  • 2 days of progressing translation of protein degradation probes into safe, effective therapeutics.

Download Agenda

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at partner@kisacoresearch.com.

Venue

San Diego, USA

Venue to be confirmed

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

We accept the following cards through Stripe:
Thursday, September 19, 2019 to Friday, September 27, 2019
Super Early Bird- Academics Access to Pre-conference deep dive into ‘Drugging the Proteasome’
$499
Super Early Bird Ends Friday 1st November 2019. Save $200.
Must be a full time academic or healthcare professional
Access to pre-conference deep dive into 'Drugging the Proteasome'
Refreshments, breakfast & lunch
Networking opportunities
Thursday, September 19, 2019 to Friday, November 1, 2019
Super Early Bird- Academics Access to 2 day conference
$699
Super Early Bird Ends Friday 1st November 2019. Save $500.
Must be a full time academic or healthcare professional
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
Thursday, September 19, 2019 to Friday, November 1, 2019
Super Early Bird- Pharma and Biotech Access to Pre-conference deep dive into ‘Drugging the Proteasome’
$799
Super Early Bird Ends Friday 1st November 2019. Save $300.
Must have an active drug pipeline
Access to pre-conference deep dive into 'Drugging the Proteasome'
Refreshments, breakfast & lunch
Networking opportunities
Thursday, September 19, 2019 to Friday, November 1, 2019
Super Early Bird- Pharma and Biotech Access to 2 day conference
$1499
Super Early Bird Ends Friday 1st November 2019. Save $700.
Must have an active drug pipeline
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
Thursday, September 19, 2019 to Friday, November 1, 2019
Super Early Bird- Service Providers Access to Pre-conference deep dive into ‘Drugging the Proteasome’
$999
Super Early Bird Ends Friday 1st November 2019. Save $600.
Access to pre-conference deep dive into 'Drugging the Proteasome'
Refreshments, breakfast & lunch
Networking opportunities
Thursday, September 19, 2019 to Friday, November 1, 2019
Super Early Bird- Service Providers Access to 2 day conference
$1999
Super Early Bird Ends Friday 1st November 2019. Save $500.
2 day conference pass
Refreshments, breakfast & lunch
Networking opportunities
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.